中访网数据 广州白云山医药集团股份有限公司于2025年12月31日发布公告，披露其附属企业广州广药二期基金股权投资合伙企业(有限合伙)参与投资设立广州荔湾广药创业投资基金合伙企业(有限合伙)的进展。根据公告，广药二期基金已与广州广药资本私募基金管理有限公司、广州天使投资母基金创业投资合伙企业(有限合伙)及广州市荔湾区产业投资基金合伙企业(有限合伙)正式签署《合伙协议》，标志着该投资基金进入实质设立阶段。根据此前董事会决议，广药二期基金的投资金额为9,950万元。该基金旨在通过合作投资，进一步拓展公司在相关领域的产业布局和投资机会。目前，广药荔湾基金尚需完成后续的工商注册登记及中国证券投资基金业协会的登记备案程序，其最终设立及运作仍存在一定的不确定性。公司表示将持续关注后续进展并履行信息披露义务。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.